NCT00877214View on ClinicalTrials.gov

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,272

Participants

Timeline

Start Date

April 1, 2009

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Follicular LymphomasImmunocytomasMarginal Zone LymphomasMantle-Cell LymphomasLymphocytic LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab

Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years

DRUG

Rituximab / observation

Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)

Trial Locations (1)

35392

StiL Head Office; Justus-Liebig-University, Giessen

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Jurgen Barth

OTHER

NCT00877214 - Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas | Biotech Hunter | Biotech Hunter